Loading...
CALA logo

Calithera Biosciences, Inc.OTCPK:CALA Stock Report

Market Cap US$2.4k
Share Price
US$0.0005
My Fair Value
n/a
1Y-16.7%
7D400.0%
Portfolio Value
​
View

Calithera Biosciences, Inc.

OTCPK:CALA Stock Report

Market Cap: US$2.4k

Calithera Biosciences (CALA) Stock Overview

Operates under a plan of liquidation that was approved in January 2023. More details

CALA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($2K)

Latest financial reports are more than a year old


CALA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Calithera Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Calithera Biosciences
Historical stock prices
Current Share PriceUS$0.0005
52 Week HighUS$0.0037
52 Week LowUS$0.0001
Beta0
1 Month Change66.67%
3 Month Change150.00%
1 Year Change-16.67%
3 Year Change-98.33%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Seeking Alpha • Oct 03

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Calithera Biosciences, Inc. (NASDAQ:CALA) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA has offered the designation for sapanisertib to treat adults with unresectable or metastatic squamous non-small cell lung cancer with a particular genetic mutation in tumors and who have previously received chemotherapy and immune checkpoint inhibitors. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling the treatments to reach patients sooner. In July, CALA announced that the patient recruitment started in Phase 2 for sapanisertib (CB-228), designed to study the candidate in certain patients with squamous non-small cell lung cancer.

Recent updates

Seeking Alpha • Oct 03

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Calithera Biosciences, Inc. (NASDAQ:CALA) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA has offered the designation for sapanisertib to treat adults with unresectable or metastatic squamous non-small cell lung cancer with a particular genetic mutation in tumors and who have previously received chemotherapy and immune checkpoint inhibitors. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling the treatments to reach patients sooner. In July, CALA announced that the patient recruitment started in Phase 2 for sapanisertib (CB-228), designed to study the candidate in certain patients with squamous non-small cell lung cancer.
Seeking Alpha • Aug 29

Calithera rises 8% after HC Wainwright upgrades rating to buy

Calithera Biosciences (NASDAQ:CALA) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 2023. The company had cash and cash equivalents of $41.8M at June 30. Calithera has two ongoing clinical development programs that are expected to provide data updates in Q1 of 2023, Ramakanth tells investors in a research note. If positive, both drugs could be evaluated in registrational studies to achieve accelerated FDA approval, says the analyst. He estimates Calithera to achieve risk-adjusted revenues of $111M by 2030. (CALA) is down ~74% YTD.
Analysis Article • Aug 17

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 17

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Aug 27

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 03

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

Calithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here could see a very strong stock appreciation, which currently the market may be overlooking.
Analysis Article • May 02

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 10

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

If you want to know who really controls Calithera Biosciences, Inc. ( NASDAQ:CALA ), then you'll have to look at the...
Analysis Article • Jan 17

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

In this article we are going to estimate the intrinsic value of Calithera Biosciences, Inc. ( NASDAQ:CALA ) by taking...
Analysis Article • Dec 13

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

CALAUS BiotechsUS Market
7D400.0%-0.5%0.5%
1Y-16.7%44.4%25.4%

Return vs Industry: CALA underperformed the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: CALA underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is CALA's price volatile compared to industry and market?
CALA volatility
CALA Average Weekly Movementn/a
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: CALA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CALA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/an/awww.calithera.com

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Calithera Biosciences, Inc. Fundamentals Summary

How do Calithera Biosciences's earnings and revenue compare to its market cap?
CALA fundamental statistics
Market capUS$2.44k
Earnings (TTM)-US$21.29m
Revenue (TTM)n/a
0.0x
P/S Ratio
0.0x
P/E Ratio

Is CALA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CALA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$28.53m
Gross Profit-US$28.53m
Other Expenses-US$7.24m
Earnings-US$21.29m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did CALA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 00:25
End of Day Share Price 2026/05/14 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Calithera Biosciences, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mohit BansalCitigroup Inc
Michael KingCitizens JMP Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.